



NOVA

University of Newcastle Research Online

nova.newcastle.edu.au

Parkington, Helena C.; Stevenson, Janet; Tonta, Mary A.; Paul, Jonathan; Butler, Trent; Maiti, Kaushik; Chan, Eng-Cheng; Sheehan, Penelope M.; Brennecke, Shaun P.; Coleman, Harold A. ; Smith, Roger "Diminished hERG K<sup>+</sup> channel activity facilitates strong human labour contractions but is dysregulated in obese women". Published in Nature Communications Vol. 5 (2014)

**Available from:** <http://dx.doi.org/10.1038/ncomms5108>

**Accessed from:** <http://hdl.handle.net/1959.13/1306719>

1 **hERG K<sup>+</sup> channel activity controls human uterine contraction in labour and this fails in obesity**

2

3 NCOMMS-12-04034

4

5 Helena C Parkington<sup>a</sup>, Mary A Tonta<sup>a</sup>, Janet Stevenson<sup>b</sup>, Jonathan Paul<sup>c</sup>, Trent Butler<sup>c</sup>, Kaushik

6 Maiti<sup>c</sup>, Eng-Cheng Chan<sup>c</sup>, Penelope M Sheehan<sup>b</sup>, Shaun P Brennecke<sup>d</sup>, Harold A Coleman<sup>a</sup>, Roger

7 Smith<sup>c</sup>.

8

9 **Short title:** hERG channel in failure to progress in human labour

10

11 <sup>a</sup>Department of Physiology, Monash University, Clayton, Vic. 3800, Australia; <sup>b</sup>Department of

12 Perinatal Medicine Pregnancy Research Centre, Royal Women's Hospital, Parkville, Vic. 3052,

13 Australia; <sup>c</sup>Mothers and Babies Research Centre, University of Newcastle, Callaghan, NSW 2308,

14 Australia; <sup>d</sup>Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Vic.

15 3010, Australia.

16

17 **Corresponding Author:** Helena C. Parkington<sup>a</sup>

18 *Address:* Department of Physiology, Monash University, Clayton, Vic 3800, Australia.

19 *Email:* helena.parkington@monash.edu

20 *Phone:* +61 3 9905 2505

21

22

23 **Abstract**

24 Human ether-a-go-go-related gene (hERG) potassium channels determine cardiac action potential  
25 and contraction duration. Human uterine contractions are underpinned by an action potential that  
26 also possesses an initial spike followed by prolonged depolarization. Here we demonstrate for the  
27 first time the presence of hERG channel proteins ( $\alpha$ -conducting and  $\beta$ -inhibitory subunits) and  
28 hERG currents in isolated patch-clamped human myometrial cells. hERG channel activity  
29 suppressed contraction amplitude and duration before labour, facilitating quiescence. During  
30 established labour  $\beta$ -inhibitory protein was markedly enhanced, resulting in reduced hERG activity  
31 that was associated with an increase in action potential and contraction duration. Thus, changes in  
32 hERG channels contribute to action potential mechanisms that produce the powerful contractions  
33 typical of labour. We also demonstrate that this system fails in women with elevated BMI, they  
34 have enhanced hERG activity, due to low  $\beta$ -inhibitory protein, which likely contributes to the poor  
35 labour outcomes observed in many obese women, necessitating cesarean delivery.

36 **Key words (not in the title):** Myometrium, cesarean delivery, KCNE2, failed labour

## 37 **Introduction**

38 Our poor understanding of the mechanisms regulating the onset and progress of human  
39 labour limits the ability to clinically control events when these mechanisms malfunction. Successful  
40 vaginal delivery demands strong contractions forcing the fetal head to dilate the cervix, separated  
41 by periods of relaxation permitting replenishment of placental blood flow<sup>1,2</sup>. A plateau phase is a  
42 particularly prominent feature of the action potential (AP) in human uterine smooth muscle  
43 (myometrium)<sup>3,4</sup> but the ionic conductances responsible for determining the amplitude, duration and  
44 rapid repolarization of the plateau to achieve relaxation between contractions, are unknown. The AP  
45 in cardiac muscle also has a prominent plateau component and the heart contracts forcefully during  
46 systole and then relaxes to permit refilling. The hERG1 potassium channel,  $I_{kr}$ , plays an important  
47 role in repolarization of the prominent plateau of the cardiac AP and hence in determining AP,  
48 contraction and diastolic durations<sup>5</sup>. We hypothesized that hERG might play a role in regulating  
49 human uterine contractions. Potassium passes through the hERG  $\alpha$ -pore-forming subunit and this is  
50 negatively regulated by a  $\beta$  ancillary subunit<sup>6,7</sup>. The level of  $\beta$  subunit protein increases in late  
51 pregnancy in mouse uterus<sup>8</sup> but the situation in labour has not been addressed. hERG has been  
52 identified in a range of smooth muscle tissues and pharmacological manipulation of its activity  
53 impacts contractile function<sup>8-15</sup>. We obtained human myometrium following cesarean delivery at  
54 term not in labour (NIL, n=43) and during established (in) labour (IL, n=27). Obese women are  
55 more likely to experience failure to go into spontaneous labour and failure to progress through to  
56 vaginal delivery (18%) compared with normal weight controls (5%). This necessitates cesarean  
57 section, with the effects especially concentrated in the first stage of labour, when powerful  
58 contractions are required to dilate the cervix and move the fetus through the narrow pelvis<sup>16-18</sup>.  
59 Thus, body mass index (BMI) was determined at first antenatal visit.

## 60 **Results**

61

62 **hERG, present in human uterus in late pregnancy, has a major influence on contractility.** To  
63 test whether hERG regulated AP duration we first recorded membrane potential and contraction  
64 simultaneously in strips of myometrium from lean women (BMI < 30) at term prior to labour onset.  
65 We used dofetilide (1  $\mu$ M) and E-4031 (1  $\mu$ M) as they are selective for hERG blockade<sup>19</sup> and have  
66 been commonly used in smooth<sup>8-15</sup> and cardiac<sup>5</sup> muscle. Both blockers caused a striking prolongation  
67 of the AP plateau and contraction (Fig. 1a), from  $0.9\pm 0.2$  min to  $2.8\pm 0.2$  min (a 2.9 fold increase,  
68  $n=10$ ,  $p<0.001$ ) (Fig. 1d). This occurred without a depolarizing effect on resting membrane potential  
69 ( $-57\pm 1$ mV, Fig. 1a). The hERG activator ICA-195574 (5  $\mu$ M)<sup>20</sup> reduced contraction duration to  
70  $54\pm 4\%$  ( $n=7$ ) (Fig. 2).

71 Myometrium from the upper region (fundus) of the uterus was obtained from four women  
72 undergoing hysterectomy following cesarean delivery and dofetilide prolonged the AP and  
73 contraction duration in a manner indistinguishable from its effects in the lower segment (Fig 1b).

74 The concentration dependence of dofetilide was tested using 20 min applications per dose in  
75 tissues from 5 women. There was a concentration dependent increase in plateau duration  
76 ( $pD_2=7.70\pm 0.11$ ), a more depolarized level of the AP plateau ( $pD_2=7.43\pm 0.23$ ), and an after-  
77 hyperpolarization more negative than that observed basally ( $pD_2=6.51\pm 0.65$ ) (Fig 1a, c). Recovery  
78 from the after-hyperpolarization resulted in a prolongation of the time until the next AP from  $6.8\pm 1.4$   
79 min basally to  $18.7\pm 1.5$  min in dofetilide ( $p<0.0001$ ,  $n=5$ ).

80 We acutely isolated myometrial cells from the same tissue samples and used whole cell patch  
81 clamp techniques to interrogate the cells for hERG channel activity. The hERG current had a  
82 maximum amplitude of  $3.6\pm 0.4$  pA/pF ( $n=10$ ) (Fig. 3a, c) and was blocked by dofetilide and E-4031  
83 (Fig. 3b, c). Current was restored to about 70% upon washout of dofetilide for 20 min. The hERG  
84 current decayed with an exponential time-course whose time-constant displayed voltage-dependence  
85 in which the time-constant changed e-fold per 73mV (Fig. 3d). These data are consistent with a

86 mechanism by which, before labour, the depolarization during the AP activates hERG which shortens  
87 the duration of the plateau and its associated contraction, facilitating quiescence.

88

89 **Reduced hERG activity is involved in the transition into normal labour.** We then asked whether  
90 changes in hERG function might contribute to the stronger, more co-ordinated contractions at the  
91 time of labour in lean women. In IL tissues dofetilide increased AP duration from  $2.8\pm 0.1$  to  $3.6\pm 0.1$   
92 min ( $p=0.005$ ,  $n=7$ ) (Fig. 1d), an increase of only 1.3 fold, and the maximum hERG current in single  
93 cells was reduced to  $1.3\pm 0.4$  pA/pF (Fig. 3c).

94 hERG (KCNH2)  $\alpha$  pore-forming subunit protein was detected in human myometrium using  
95 Western blotting (Fig. 4a). The plasma membrane-inserted glycosylated 155 KDa form (Fig. 4ci) and  
96 the endoplasmic reticulum-stored poorly-glycosylated 135 KDa form (Fig. 4cii) occurred and these  
97 bands were not observed in the presence of antibody blocking peptide (Fig. 4a). hERG  $\alpha$ -subunit  
98 protein levels were unchanged IL ( $n=10$ ) compared with NIL ( $n=10$ , Fig. 4Ci, ii). Similarly, hERG  $\alpha$   
99 subunit mRNA did not differ IL versus NIL (Fig. 4d).

100 Expression of  $\beta$  auxiliary inhibitory subunit (KCNE2) protein was significantly enhanced IL  
101 versus NIL ( $p=0.0001$ , Fig. 4b, ciii). The  $\beta$  auxiliary subunit reduces current flow through the  $\alpha$   
102 subunit of the hERG channel<sup>6,7</sup> and its increase in the IL samples explains the suppression of hERG  
103 current and consequent prolongation of the AP plateau and contraction in labour. These data  
104 demonstrate that hERG contributes to suppression of uterine contractile strength before labour and  
105 this effect is reduced in labour in lean women, facilitating the strong contractions required for vaginal  
106 delivery.

107

108 **hERG effectiveness is increased as BMI increases.** Women with elevated BMI are more likely to  
109 have longer pregnancies, necessitating induction of labour<sup>16-18</sup>. Here we asked whether  
110 inappropriate hERG function in late pregnancy could contribute to this effect of obesity. We used  
111 the dofetilide-induced increase in AP plateau duration as a measure of hERG activity and plotted

112 this against BMI. In tissues from women at term but NIL there was a strong positive correlation  
113 between dofetilide-induced increase in AP plateau duration and BMI. BMI explained 89% of the  
114 variance in plateau duration evoked by dofetilide ( $r^2=0.89$ ,  $p<0.0001$ , Fig. 5a). Importantly, and  
115 consistent with this, hERG current density in isolated cells increased as BMI increased ( $r^2=0.59$ ,  
116  $p=0.001$ , Fig. 5b).

117 This functional effect of elevated BMI was supported by a marked increase in hERG  $\alpha$   
118 subunit protein ( $r^2=0.62$ ,  $p<0.0001$ , Fig. 6a) and a decrease in inhibitory KCNE2 protein expression  
119 ( $r^2=0.33$ ,  $p=0.004$ , Fig. 6b) with increasing BMI. The reduction in  $\beta$  subunit and increase in hERG  
120 expression with increasing BMI is consistent with greater hERG activity which would shorten AP  
121 plateau and contraction duration, thus diminishing the prospects for strong uterine contraction  
122 development in women with elevated BMI.

123

124 **hERG activity persists at the time of labour in myometrium from obese women.** In labour,  
125 women with a higher BMI more often fail to progress through to vaginal delivery, necessitating  
126 cesarean section<sup>16,17</sup>. The dramatic effects of BMI on hERG activity and on AP and contraction  
127 duration before labour prompted the critical question; does this suppressive effect of hERG persist  
128 in labour and account for the failure to progress in labour in obesity? In our cohort of lean women,  
129 BMI  $<30$ , the reason for cesarean delivery IL was fetal distress (indicated by cardiotocography,  
130 CTG) in 11/16 women, with failure to progress (FTP) in only 5 of the 16 (Fig. 6d). In contrast, for  
131 women with BMI  $>30$ , FTP occurred in 10/11 cases (Fig. 6d).

132 Dofetilide had only a modest effect on AP and contraction duration in myometrial strips  
133 from lean women IL (Fig. 6e), but was more effective in strips from obese women (Fig. 6f). The  
134 increase in AP plateau duration by dofetilide in IL tissues increased progressively as BMI increased  
135 ( $r^2=0.82$ ,  $p<0.0001$ , Fig. 6c). While the increase in  $\alpha$  subunit of hERG with BMI was similar in IL  
136 ( $r^2=0.76$ ,  $p<0.0001$ ) and NIL tissues ( $r^2=0.62$ ,  $p<0.0001$ , Fig. 6a), levels of  $\beta$  subunit protein  
137 declined as BMI increased to a greater extent in IL samples ( $r^2=0.57$ ,  $p=0.001$ , Fig. 6b). Thus, for

138 larger BMI there is little difference in levels of  $\beta$ -subunit protein between IL and NIL. Since the  $\beta$   
139 subunit suppresses hERG current, its increase in lean labour removes the hERG termination of the  
140 action potential and contraction permitting longer and likely more effective contractions, ensuring  
141 vaginal delivery. The strong decrease in  $\beta$  subunit protein levels in women with elevated BMI  
142 effectively means that the myometrium does not progress into labour and this provides a  
143 mechanistic explanation for the failure to progress in labour in many women with increasing BMI.

144 **Discussion**

145 Here we provide compelling evidence that hERG plays a significant role in the relative  
146 quiescence of the uterus before labour, essential for development of the fetus to maturity. This is  
147 achieved by the ability of hERG to shorten the plateau phase of the AP, providing insufficient time  
148 for the development of a large contraction in human myometrium. The resulting contraction is short  
149 and weak. The transition of the myometrium into a labouring phenotype is accompanied by changes  
150 in hERG activity, whereby hERG-associated suppression of the uterine AP is markedly reduced. In  
151 fact, when we blocked hERG in not in labour tissues, the AP duration was transformed into a basal  
152 labour-like duration (see Fig. 1d). This labour-associated reduction in hERG effectiveness occurs  
153 despite maintained levels of hERG  $\alpha$  pore-forming subunit protein and mRNA. Rather, there is a  
154 marked increase in  $\beta$  auxiliary subunit expression, which suppresses hERG current<sup>6</sup>.

155 Blockade of hERG with dofetilide or E4031 results in depolarization in rat stomach<sup>12</sup>,  
156 bovine epididymal<sup>11</sup>, and opossum esophageal<sup>9</sup> smooth muscles. This likely accounts for the  
157 increase in contraction frequency in most smooth muscle tissues studied<sup>8,10,14</sup>. In contrast, human  
158 myometrium was hyperpolarized between APs in the presence of dofetilide, which was  
159 accompanied by a decrease in contraction frequency. This hyperpolarization is likely a consequence  
160 of the prolonged nature of the human uterine AP plateau in the presence of hERG blockers, rather  
161 than as a direct result of hERG blockade. This interpretation arises from our previous finding that  
162 application of prostaglandin F<sub>2 $\alpha$</sub>  to human myometrial strips results in prolongation of the AP  
163 plateau and an after-hyperpolarization between APs, reminiscent of dofetilide application here. We  
164 established that the prostaglandin effect is due to an increase in Na/K ATPase activity as a result of  
165 AP plateau lengthening<sup>21</sup>. Thus, understandable differences in ion channel type and density occur in  
166 human uterine versus other smooth muscles<sup>2</sup>.

167 Many smooth muscle tissues display plateau-like electrical activity which dictates the  
168 amplitude and duration of contraction<sup>22-25</sup>, and this includes the circular muscle layer of the mouse  
169 myometrium<sup>24</sup>. While the level of the plateau in many cases is close to that observed in human

170 myometrium,  $-25$  to  $-30$ mV, a striking feature of the AP plateau in human myometrium is the  
171 rapidity of repolarization. Block of hERG in guinea-pig gall bladder increases the duration of a  
172 proportion of pacemaker depolarisations permitting an increase in the number of superimposed  
173 spike APs<sup>14</sup>. In human jejunum E4013 increases the amplitude of all pacemaker depolarisations,  
174 again increasing the number of spike APs<sup>10</sup>. Taken together, the use of hERG blockers in the  
175 present study provides insights into the unique nature of the plateau-AP in human uterus,  
176 demonstrates an important role for hERG potassium channels, and provides an impetus for further  
177 study.

178         The voltage dependence of the rate of deactivation of hERG current in smooth muscle cells  
179 is much weaker than that of hERG in cardiomyocytes<sup>13,15,26</sup>. Furthermore, in mouse myometrium  
180 the voltage dependence appears weaker in late pregnancy compared with non-pregnant tissue<sup>8</sup>. Our  
181 results show a weak voltage dependence for myometrium of women at term, consistent with the  
182 earlier studies in late pregnant mouse myometrium<sup>8</sup>.

183         Activation of protein kinase A (PKA) increases hERG protein phosphorylation, which  
184 facilitates hERG incorporation into the plasma membrane<sup>27</sup>. PKA may also influence activity of the  
185 inhibitory  $\beta$  subunit<sup>28</sup>. Within the myometrium, cAMP activation of PKA pathways is involved in  
186 maintaining relaxation during pregnancy, and components of PKA signalling are down regulated in  
187 human labour<sup>29</sup> permitting strong contractions. It remains to be determined if regulation of hERG  
188 activity in the transition into human labour involves the cAMP/PKA signalling system.

189         Obesity is an increasing scourge within the population in general and consequently is  
190 increasing in the pregnant population. Obesity is largely responsible for the recent increasing need  
191 for cesarean delivery, which increases maternal and neonatal morbidity and can predispose to  
192 problems for future pregnancies<sup>30,31</sup>. The hERG  $\beta$  subunit is upregulated by estrogen<sup>32</sup>, and the  
193 estrogen profile can be dysfunctional in high BMI pregnancies<sup>33</sup>. Obesity is associated with  
194 increased circulating levels of cholesterol and leptin<sup>34</sup>. Cholesterol levels are higher in caveoli<sup>35</sup>, the  
195 location of hERG  $\alpha$  and  $\beta$  subunit insertions<sup>36</sup>. Direct interaction may occur between membrane

196 lipids and amino acids in membrane-traversing domains of ion channel proteins<sup>37</sup>, and hERG  
197 channel kinetics are sensitive to the cholesterol content of the plasma membrane<sup>36</sup>. Disruption of  
198 membrane cholesterol suppresses human and rat uterine contractions<sup>38</sup>. Leptin is also increased in  
199 obesity and in pregnancy<sup>39</sup>, and leptin<sup>40</sup> and the adipokine apelin<sup>41</sup> also suppress human uterine  
200 contractions. The role of these factors in regulating hERG  $\alpha$  and  $\beta$  subunits in human myometrium  
201 warrants investigation.

202         Here we demonstrate for the first time the presence of hERG protein and  $\beta$  ancillary subunit  
203 protein in human myometrium in late pregnancy and labour. Our results demonstrate the dynamic  
204 contribution of hERG channels, and the  $\beta$  subunit in particular, to uterine smooth muscle function  
205 in the progression into labour. Importantly, we show that hERG is present and influences  
206 contractility, not only in the lower segment but also within the main fundus region of the uterus.  
207 Effectively, blockade of hERG by dofetilide transforms the pre labour myometrium into the  
208 labouring phenotype (Fig. 1d). Significantly, our results draw together a strong link between obesity  
209 and hERG function in human myometrium. Thus, our data present compelling evidence implicating  
210 hERG channels in the established clinical problem of the rising incidence of cesarean delivery in  
211 obesity and provides a focus for further investigation. We provide a solid mechanism towards  
212 understanding the poor labour outcomes in obese women.

213 **Methods**

214 Studies were approved by the Royal Women's Hospital Research Ethics Committee, and the  
215 Hunter and New England Area Research Committee, adhering to guidelines of the Declaration of  
216 Helsinki. Participants gave informed written consent for collection of myometrial samples prior to  
217 surgery and tissue collection. BMI was obtained at first hospital visit. Women undergoing term  
218 (37–40 weeks gestation) elective cesarean delivery with no signs of labor formed the NIL cohort,  
219 while women undergoing term emergency cesarean section following the spontaneous  
220 establishment of labor formed the IL cohort. Infection, hypertension, diabetes were exclusion  
221 criteria. Clinical indications for elective NIL cesarean delivery were previous cesarean section,  
222 3<sup>rd</sup>/4<sup>th</sup> degree tear, breech, while clinical indications for emergency IL cesarean section were fetal  
223 distress or failure to progress in labor. Following delivery of the placenta, all women were  
224 administered 5 units of oxytocin (syntocinon) directly into an intravenous line as part of standard  
225 care for the prevention of post-partum hemorrhage. Myometrial biopsies were excised 3–5 min after  
226 administration of oxytocin, thus all samples were briefly exposed to oxytocin. Myometrial samples  
227 (5×5×10 mm) from the lower uterine segment of term singleton pregnancies were collected. A  
228 portion of the sample was immediately frozen in liquid nitrogen for subsequent protein analysis,  
229 while the remaining tissue was immediately taken to the lab and electrophysiology and contraction  
230 studies were commenced within 1 h.

231 **Strip electrophysiology and contraction.** Membrane potential was recorded from smooth muscle  
232 cells in strips of tissue (3×1×0.5mm), using glass intracellular microelectrodes filled with 1M KCl  
233 (resistances ~100MΩ) to impale a single smooth muscle cell within the strip, and tension was  
234 recorded simultaneous (force transducer, AE801, SensoNor, Horton, Norway) as previously  
235 described<sup>21</sup>. The microelectrode was connected to an Axoclamp 2B amplifier (Axon Instruments,  
236 CA), low-pass filtered at 3KHz and digitized at 1KHz (Digidata 1440A, Molecular Devices, CA).  
237 Strips were set at 0.2 mN basal tension and continuously superfused at 3 ml/min and 36°C with  
238 physiological salt solution (PSS) containing (mM); NaCl 120, KCl 5, NaHCO<sub>3</sub> 25, KH<sub>2</sub>PO<sub>4</sub> 1,

239 MgSO<sub>4</sub> 1.2, CaCl<sub>2</sub> 2.5, glucose 11, gassed with 95% O<sub>2</sub>, 5% CO<sub>2</sub>, pH 7.4. Concentration response  
240 curves to dofetilide were fitted to a sigmoid curve, using the least-squares method and pD<sub>2</sub> (-log  
241 EC<sub>50</sub>) was calculated (GraphPad Prism).

242 **Patch clamp.** Single smooth muscle cells were isolated (2 mg/mL type I collagenase, 2mg/ml  
243 trypsin inhibitor, 1mg/ml fatty acid-free albumin at 37°C for 50min) and studied within 6h. The  
244 cells were voltage clamped using whole cell or nystatin-perforated patches (Axopatch 200 and  
245 Digidata 1322A, pClamp 9) following. Cells were superfused with PSS (mM); NaCl 137, NaHCO<sub>3</sub>  
246 4, NaH<sub>2</sub>PO<sub>4</sub> 0.3, KCl 5.4, KH<sub>2</sub>PO<sub>4</sub> 0.44, MgCl<sub>2</sub> 0.5, MgSO<sub>4</sub> 4, glucose 5.6, HEPES 10, CaCl<sub>2</sub> 1.3,  
247 at pH 7.4 and 22°C. Patch electrode solution contained (mM): KCl 130, MgCl<sub>2</sub> 1.2, ATP 3, EGTA  
248 5, HEPES 10. To enhance K<sup>+</sup> currents, the PSS contained (mM): KCl 140, MgCl<sub>2</sub> 1, HEPES 10,  
249 glucose 10, CaCl<sub>2</sub> 0.1 immediately before testing. Cells were held at 0mV and stepped in 10mV  
250 increments to -120mV<sup>8,9</sup>.

251 **Western blotting.** Protein analysis was performed as previously outlined<sup>42</sup>. Rabbit anti-K<sub>v</sub>11.1  
252 (hERG) (APC-109, 1:2000 dilution, Alomone Laboratories, Israel) and rabbit anti-KCNE2 (APC-  
253 054, 1:200 dilution, Alomone Labs) were applied in the presence or absence of blocking peptide  
254 (2μg/1μg antibody). Protein was expressed relative to α smooth muscle actin and analysed using t-  
255 tests with unequal variance. mRNA abundance was expressed relative to 18S rRNA and analyzed  
256 using the ΔΔCt method.

257 **Reagents:** Stock solutions of blockers and activators of hERG channels were prepared in DMSO at  
258 x1000 concentration or dH<sub>2</sub>O as appropriate. The hERG blockers dofetilide and E-4031, activators  
259 PD-118057, NS1643 and ICA-195574, DMSO and all solution reagents were purchased from  
260 Sigma-Aldrich (St Louis, USA). DMSO 1:1,000 dilution was tested for the appropriate time  
261 exposure in every tissue. There was no detectable effect of DMSO on activity in whole tissues or  
262 isolated single smooth muscle cells.

263 **Statistical analysis.** Data were analysed using GraphPad Prism and GraphPad InStat (GraphPad  
264 Software Inc. SanDiego, CA, USA). For all data sets, equality of standard deviations and Gaussian

265 distribution, using the Kolmogorov/Smirnov method, were tested. Data are expressed as mean and  
266 standard error of the mean (SEM). Throughout,  $n$  represents the number of women studied and  $p <$   
267 0.05 was accepted as statistically significant. Experimenters were blinded to the clinical status of  
268 the women (NIL, IL, BMI values) and the status was provided by Dr P Sheehan at a stage in the  
269 analysis when it was required. Effects of DMSO diluent (0.01%) were tested in every tissue and  
270 were negative. For electrophysiology and contractility studies, correlation between dofetilide-  
271 induced plateau lengthening and BMI was determined using least products regression. Repeated  
272 measures ANOVA was used to compare between NIL versus IL. Two-way ANOVA was used to  
273 test hERG currents and dofetilide effects versus BMI, with Bonferonni *post-hoc* testing. Unpaired  
274 or paired Student t-tests were used for testing differences.

275 **References**

- 276 1. Smith, R. Parturition. *N. Engl. J. Med.* **356**, 271-283 (2007).  
 277 2. Young, R.C. Myocytes, myometrium, and uterine contractions. *Ann. N. Y. Acad. Sci.* **1101**,  
 278 72-84 (2007).  
 279 3. Parkington, H.C., Tonta, M.A., Brennecke, S.P. & Coleman, H.A. Contractile activity,  
 280 membrane potential, and cytoplasmic calcium in human uterine smooth muscle in the  
 281 third trimester of pregnancy and during labor. *Am. J. Obstet. Gynecol.* **181**, 1445-1451  
 282 (1999).  
 283 4. Shmygol, A., Blanks, A.M., Bru-Mercier, G., Gullam, J.E. & Thornton, S. Control of uterine  
 284 Ca<sup>2+</sup> by membrane voltage: toward understanding the excitation-contraction coupling  
 285 in human myometrium. *Ann. N. Y. Acad. Sci.* **1101**, 97-109 (2007).  
 286 5. Sanguinetti, M.C. & Tristani-Firouzi, M. hERG potassium channels and cardiac  
 287 arrhythmia. *Nature* **440**, 463-469 (2006).  
 288 6. Abbott, G.W., *et al.* MiRP1 forms IKr potassium channels with HERG and is associated  
 289 with cardiac arrhythmia. *Cell* **97**, 175-187 (1999).  
 290 7. Jiang, M., *et al.* KCNE2 protein is expressed in ventricles of different species, and changes  
 291 in its expression contribute to electrical remodeling in diseased hearts. *Circulation* **109**,  
 292 1783-1788 (2004).  
 293 8. Greenwood, I.A., Yeung, S.Y., Tribe, R.M. & Ohya, S. Loss of functional K<sup>+</sup> channels  
 294 encoded by ether-a-go-go-related genes in mouse myometrium prior to labour onset. *J.*  
 295 *Physiol.* **587**, 2313-2326 (2009).  
 296 9. Akbarali, H.I., Thatte, H., He, X.D., Giles, W.R. & Goyal, R.K. Role of HERG-like K<sup>+</sup> currents  
 297 in opossum esophageal circular smooth muscle. *Am. J. Physiol. Cell Physiol.* **277**, C1284-  
 298 1290 (1999).  
 299 10. Farrelly, A.M., *et al.* Expression and function of KCNH2 (HERG) in the human jejunum.  
 300 *Am. J. Physiol. Gastrointest. Liver Physiol.* **284**, G883-895 (2003).  
 301 11. Mewe, M., *et al.* Erg K<sup>+</sup> channels modulate contractile activity in the bovine epididymal  
 302 duct. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **294**, R895-904 (2008).  
 303 12. Ohya, S., Asakura, K., Muraki, K., Watanabe, M. & Imaizumi, Y. Molecular and functional  
 304 characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle. *Am.*  
 305 *J. Physiol. Gastrointest. Liver Physiol.* **282**, G277-287 (2002).  
 306 13. Ohya, S., Horowitz, B. & Greenwood, I.A. Functional and molecular identification of ERG  
 307 channels in murine portal vein myocytes. *Am. J. Physiol. Cell Physiol.* **283**, C866-877  
 308 (2002).  
 309 14. Parr, E., Pozo, M.J., Horowitz, B., Nelson, M.T. & Mawe, G.M. ERG K<sup>+</sup> channels modulate  
 310 the electrical and contractile activities of gallbladder smooth muscle. *Am. J. Physiol.*  
 311 *Gastrointest. Liver Physiol.* **284**, G392-398 (2003).  
 312 15. Shoeb, F., Malykhina, A.P. & Akbarali, H.I. Cloning and functional characterization of the  
 313 smooth muscle ether-a-go-go-related gene K<sup>+</sup> channel. Potential role of a conserved  
 314 amino acid substitution in the S4 region. *J. Biol. Chem.* **278**, 2503-2514 (2003).  
 315 16. Jie, Z., Kendrick, A., Quenby, S. & Wray, S. Contractility and calcium signaling of human  
 316 myometrium are profoundly affected by cholesterol manipulation: implications for  
 317 labor? *Reprod. Sci.* **14**, 456-466 (2007).  
 318 17. Higgins, C.A., *et al.* Maternal obesity and its relationship with spontaneous and oxytocin-  
 319 induced contractility of human myometrium in vitro. *Reprod. Sci.* **17**, 177-185 (2010).  
 320 18. Fyfe, E.M., *et al.* Risk of first-stage and second-stage cesarean delivery by maternal body  
 321 mass index among nulliparous women in labor at term. *Obstet. Gynecol.* **117**, 1315-1322  
 322 (2011).

- 323 19. Gutman, G.A., *et al.* International Union of Pharmacology. LIII. Nomenclature and  
324 molecular relationships of voltage-gated potassium channels. *Pharmacol. Rev.* **57**, 473-  
325 508 (2005).
- 326 20. Garg, V., Sachse, F.B. & Sanguinetti, M.C. Tuning of EAG K<sup>+</sup> channel inactivation:  
327 molecular determinants of amplification by mutations and a small molecule. *J. Gen.*  
328 *Physiol.* **140**, 307-324 (2012).
- 329 21. Parkington, H.C., Tonta, M.A., Davies, N.K., Brennecke, S.P. & Coleman, H.A.  
330 Hyperpolarization and slowing of the rate of contraction in human uterus in pregnancy  
331 by prostaglandins E<sub>2</sub> and F<sub>2α</sub>: involvement of the Na<sup>+</sup> pump. *J. Physiol.* **514**, 229-243  
332 (1999).
- 333 22. Beckett, E.A., Hollywood, M.A., Thornbury, K.D. & McHale, N.G. Spontaneous electrical  
334 activity in sheep mesenteric lymphatics. *Lymphat. Res. Biol.* **5**, 29-43 (2007).
- 335 23. Lang, R.J., Hashitani, H., Tonta, M.A., Parkington, H.C. & Suzuki, H. Spontaneous electrical  
336 and Ca<sup>2+</sup> signals in typical and atypical smooth muscle cells and interstitial cell of Cajal-  
337 like cells of mouse renal pelvis. *J. Physiol.* **583**, 1049-1068 (2007).
- 338 24. Osa, T. & Katase, T. Physiological comparison of the longitudinal and circular muscles of  
339 the pregnant rat uterus. *Jpn J. Physiol.* **25**, 153-164 (1975).
- 340 25. Shabir, S., Borisova, L., Wray, S. & Burdyga, T. Rho-kinase inhibition and  
341 electromechanical coupling in rat and guinea-pig ureter smooth muscle: Ca<sup>2+</sup>-dependent  
342 and -independent mechanisms. *J. Physiol.* **560**, 839-855 (2004).
- 343 26. Yeung, S.Y. & Greenwood, I.A. Pharmacological and biophysical isolation of K<sup>+</sup> currents  
344 encoded by ether-a-go-go-related genes in murine hepatic portal vein smooth muscle  
345 cells. *American journal of physiology. Cell physiology* **292**, C468-476 (2007).
- 346 27. Chen, J., *et al.* PKA phosphorylation of HERG protein regulates the rate of channel  
347 synthesis. *Am. J. Physiol. Heart Circ. Physiol.* **296**, H1244-1254 (2009).
- 348 28. Cui, J., *et al.* Analysis of the cyclic nucleotide binding domain of the HERG potassium  
349 channel and interactions with KCNE2. *J. Biol. Chem.* **276**, 17244-17251 (2001).
- 350 29. MacDougall, M.W., Europe-Finner, G.N. & Robson, S.C. Human myometrial quiescence  
351 and activation during gestation and parturition involve dramatic changes in expression  
352 and activity of particulate type II (RII alpha) protein kinase A holoenzyme. *J. Clin.*  
353 *Endocrinol. Metab.* **88**, 2194-2205 (2003).
- 354 30. Arrowsmith, S., Wray, S. & Quenby, S. Maternal obesity and labour complications  
355 following induction of labour in prolonged pregnancy. *BJOG* **118**, 578-588 (2011).
- 356 31. McIntyre, H.D., Gibbons, K.S., Flenady, V.J. & Callaway, L.K. Overweight and obesity in  
357 Australian mothers: epidemic or endemic? *Med. J. Aust.* **196**, 184-188 (2012).
- 358 32. Kundu, P., *et al.* Hormonal regulation of cardiac KCNE2 gene expression. *Mol. Cell.*  
359 *Endocrinol.* **292**, 50-62 (2008).
- 360 33. Wu, J., *et al.* Correlates of pregnancy oestrogen, progesterone and sex hormone-binding  
361 globulin in the USA and China. *Eur. J. Cancer Prev.* **11**, 283-293 (2002).
- 362 34. Meyer, B.J., *et al.* Maternal obesity is associated with the formation of small dense LDL  
363 and hypoadiponectinemia in the third trimester. *J. Clin. Endocrinol. Metab.* **98**, 643-652  
364 (2013).
- 365 35. Howitt, L., Grayson, T.H., Morris, M.J., Sandow, S.L. & Murphy, T.V. Dietary obesity  
366 increases NO and inhibits BKCa-mediated, endothelium-dependent dilation in rat  
367 cremaster muscle artery: association with caveolins and caveolae. *Am. J. Physiol. Heart*  
368 *Circ. Physiol.* **302**, H2464-2476 (2012).
- 369 36. Balijepalli, R.C., *et al.* Kv11.1 (ERG1) K<sup>+</sup> channels localize in cholesterol and sphingolipid  
370 enriched membranes and are modulated by membrane cholesterol. *Channels (Austin)* **1**,  
371 263-272 (2007).
- 372 37. Dart, C. Lipid microdomains and the regulation of ion channel function. *J. Physiol.* **588**,  
373 3169-3178 (2010).

- 374 38. Noble, K., Zhang, J. & Wray, S. Lipid rafts, the sarcoplasmic reticulum and uterine calcium  
375 signalling: an integrated approach. *J. Physiol.* **570**, 29-35 (2006).
- 376 39. Hardie, L., Trayhurn, P., Abramovich, D. & Fowler, P. Circulating leptin in women: a  
377 longitudinal study in the menstrual cycle and during pregnancy. *Clin. Endocrinol. (Oxf.)*  
378 **47**, 101-106 (1997).
- 379 40. Moynihan, A.T., Hehir, M.P., Glavey, S.V., Smith, T.J. & Morrison, J.J. Inhibitory effect of  
380 leptin on human uterine contractility in vitro. *Am. J. Obstet. Gynecol.* **195**, 504-509  
381 (2006).
- 382 41. Hehir, M.P. & Morrison, J.J. The adipokine apelin and human uterine contractility. *Am. J.*  
383 *Obstet. Gynecol.* **206**, 359 e351-355 (2012).
- 384 42. Paul, J., *et al.* Phasic phosphorylation of caldesmon and ERK 1/2 during contractions in  
385 human myometrium. *PLoS ONE* **6**, e21542 (2011).

386

387

388 **Acknowledgements**


389 The authors thank the obstetricians and midwives from the John Hunter Hospital, and Ms Sue  
390 Duggan and Ms Moira Stewart, the research midwives at the Royal Women's Hospital. We thank  
391 the participants who donated samples toward this study. This study was supported by National  
392 Health & Medical Research Council of Australia funding to RS and HCP and SPB.

393

394 **Author Contributions:** Conceived and designed experiments: RS, HCP, JP, ECC. Sample  
395 collection: JP, TB, ECC, KM, PJS, SPB, MAT SD, MS. Bioassays and protein analysis: HCP,  
396 HAC, JP, TB, KM, ECC, MAT. Data analysis: JP, HAC, HCP. Provided reagents and materials:  
397 HCP, RS. Manuscript writing and comment: HCP, RS, JP, HAC, TB, PJS, SPB.

398

399 **Disclosure of Interests:** Roger Smith has patents held at the University of Newcastle related to the  
400 use of hERG modulators in pregnancy. The other authors have nothing to disclose.



401

402 **Figure 1: Significant influence of hERG on human uterine contractility.** a. Blockade of

403 hERG with dofetilide (1  $\mu$ M) prolonged the plateau phase of the action potential (AP) (upper

404 trace) and contraction (lower trace) recorded simultaneously. b. Similar effects in a strip from

405 the fundus of the uterus. c. Dofetilide induced a concentration-dependent increase in AP


406 plateau duration, an increase in the level of plateau depolarization and an after-

407 hyperpolarization between APs ( $n = 5$ ). d. hERG block with dofetilide caused a greater

408 prolongation of the AP plateau before (NIL) versus during labour (IL), effectively turning a

409 NIL AP into an IL AP. Mean  $\pm$  SEM.


410



411

412 **Figure 2: Reduction in plateau duration by activation of hERG.** Action potential plateau  
413 and contraction durations were reduced in the presence of the hERG activator ICA-195574.


414



415

416 **Figure 3: hERG currents in isolated human myometrial cells. a.** Following depolarization  
 417 to 0mV, in 140mM extracellular K<sup>+</sup> solution, progressive step repolarizations to -120mV  
 418 evoked currents **b.** that were blocked by dofetilide, indicating hERG. **c.** hERG current was  
 419 reduced to one third in labour and blocked by dofetilide 1  $\mu$ M and E4031 1 $\mu$ M. **d.** The voltage  
 420 dependence of the time-constant of deactivation changed e-fold per 73mV (further analysis of  
 421 data in **a** not in labour). N = number of women tested, mean  $\pm$  SEM.


422



423

424 **Figure 4: hERG  $\alpha$  and  $\beta$  subunit protein levels in human myometrium. a.** Plasma  
 425 membrane-inserted glycosylated 155 KDa and poorly-glycosylated 135 KDa forms of hERG  
 426 (upper trace) and  $\alpha$  actin 44 KDa (lower trace, loading control) in myometrium from lean  
 427 women. R, rat heart; IL, in labour and NIL, not in labour myometrium; A, human adipose tissue  
 428 positive control; B blocking protein; C antibody only. **b.** KCNE2  $\beta$  subunit 22 KDa (upper  
 429 trace); O, obese, BMI >30. **c.** Levels of pore-forming hERG  $\alpha$ -subunit (KCNH2) 155 KDa (i) and  
 430 135 KDa (ii) were not different before (NIL) versus during labour (IL). (iii) KCNE2 was  
 431 significantly increased IL. **d.** hERG  $\alpha$ -subunit mRNA was not different NIL versus IL. Mean  $\pm$   
 432 SEM.

433




434

435 **Figure 5: BMI positively associated with increased hERG function in human myometrium. a.**

436 The increase in plateau duration by dofetilide at term not in labour (NIL) was tightly correlated with

437 increasing BMI. **b.** hERG current was similarly increased with increasing BMI.

438



439

440 **Figure 6: hERG activity in myometrium persists in labour in obese women.** **a.** hERG 155 KDa  
 441 protein increased with BMI in a similar manner before (NIL) and during labour (IL). **b.** While  
 442 KCNE2 protein was increased IL in lean tissue, this increase failed to occur as BMI increased. **c.**  
 443 The ability of dofetilide to increase AP plateau duration increased, indicating greater hERG and  
 444 suppression of the AP and contraction with increasing BMI. **d.** All but one woman with BMI >30  
 445 failed to progress (FTP) in labour, while fetal distress (measured by cardiotocography, CTG)  
 446 necessitated cesarean delivery in 11/16 lean. **e.** Dofetilide was less effective in tissue from lean  
 447 women IL compared with **f.** tissue from obese women.